Table 2.

Results of meta-analysis

Outcome of interest	No. of studies	No. of patients	OR	95%CI	P-value	I2 (%)
Overall morbidity	10[8-10,16-18,20,22-24]	Bev + = 452, Bev - = 494	1.17	1.00, 1.37	0.06	0
Severe complication	8[8-10,16,17,20,22,23]	Bev + = 390, Bev - = 421	1.57	0.97, 2.53	0.07	18
Wound complication	6[8-10,16,22,23]	Bev + = 269, Bev - = 296	1.43	0.82, 2.50	0.21	0
Bleeding/thromboembolic complication	5[8-10,23,24]	Bev + = 218, Bev - = 284	0.99	0.41, 2.38	0.98	0
Cardiovascular complication	2[16,23]	Bev + = 148, Bev - = 141	1.14	0.23, 5.56	0.88	0
Pulmonary complication	6[8,16,18,20,23,24]	Bev + = 247, Bev - = 267	1.10	0.60, 2.02	0.77	0
Renal or urinary complication	6[8,16,18,20,23,24]	Bev + = 247, Bev - = 267	0.73	0.24, 2.23	0.58	0
Hepatic dysfunction	5[16-18,20,23]	Bev + = 223, Bev - = 219	0.48	0.22, 1.05	0.07	0
Mortality	10[8-10,16-18,20,22-24]	Bev + = 452, Bev - = 494	0.63	0.16, 2.56	0.52	0
Overall sinusoidal dilation	6[15,19-21,23,24]	Bev + = 265, Bev - = 395	0.53	0.38, 0.75	< 0.001	0
Moderate or severe sinusoidal dilation	6[15,18-21,24]	Bev + = 267,Bev - = 387	0.34	0.19,0.64	< 0.001	46

OR: Odds ratio; Bev: Bevacizumab.